Issue 2, 2012
From the journal:

MedChemComm

Pharmacokinetics of Agelastatin A in the central nervous system

Zhimin Li,a   Takuma Kamon,c   David A. Personett,a   Thomas Caulfield,a   John A. Copland,a   Takehiko Yoshimitsuc  and  Han W. Tun*b  

* Corresponding authors

a Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA

b Department of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida, USA
E-mail: tun.han@mayo.edu
Fax: +1 904 953 2315
Tel: +1 904 953 6460

c Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan

Abstract

Agelastatin A (AA) is an anti-neoplastic agent with anti-osteopontin (OPN) activity. Brain tumors often express OPN significantly. A comprehensive chemoinformatic analysis followed by in vivo pharmacokinetic evaluations in mice is performed. CNS penetration of AA is about 10%. AA should be further tested for activity against brain tumors.

Graphical abstract: Pharmacokinetics of Agelastatin A in the central nervous system

About
Cited by
Related
Download options Please wait...

Article information

DOI
https://doi.org/10.1039/C1MD00240F
Article type
Concise Article
Submitted
20 Sep 2011
Accepted
01 Nov 2011
First published
23 Nov 2011

Med. Chem. Commun., 2012,3, 233-237

Permissions

Request permissions

Pharmacokinetics of Agelastatin A in the central nervous system

Z. Li, T. Kamon, D. A. Personett, T. Caulfield, J. A. Copland, T. Yoshimitsu and H. W. Tun, Med. Chem. Commun., 2012, 3, 233 DOI: 10.1039/C1MD00240F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements